ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,277,751 | -12.2% | 47,080 | -0.5% | 0.00% | 0.0% |
| Q2 2023 | $1,454,771 | -22.5% | 47,325 | -9.2% | 0.00% | 0.0% |
| Q1 2023 | $1,877,091 | -9.0% | 52,098 | -0.1% | 0.00% | -33.3% |
| Q4 2022 | $2,061,956 | +6.7% | 52,175 | +8.5% | 0.00% | 0.0% |
| Q3 2022 | $1,931,694 | -6.7% | 48,076 | -2.4% | 0.00% | -40.0% |
| Q2 2022 | $2,071,000 | -52.6% | 49,247 | -56.1% | 0.01% | -44.4% |
| Q1 2022 | $4,367,000 | -3.8% | 112,100 | -1.6% | 0.01% | 0.0% |
| Q4 2021 | $4,541,000 | +53.4% | 113,952 | +39.1% | 0.01% | +50.0% |
| Q3 2021 | $2,960,000 | -13.2% | 81,909 | -1.6% | 0.01% | -14.3% |
| Q2 2021 | $3,412,000 | +8.2% | 83,251 | +15.1% | 0.01% | +16.7% |
| Q1 2021 | $3,154,000 | +138.0% | 72,320 | +173.3% | 0.01% | +100.0% |
| Q4 2020 | $1,325,000 | +48.7% | 26,460 | +25.0% | 0.00% | +50.0% |
| Q3 2020 | $891,000 | – | 21,173 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |